Richard Thomas Williams - Jun 1, 2023 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
Chief Medical Officer
Signature
/s/ Mark A. Meltz, as attorney-in-fact
Stock symbol
KNTE
Transactions as of
Jun 1, 2023
Transactions value $
-$2,326
Form type
4
Date filed
6/5/2023, 05:01 PM
Previous filing
Mar 3, 2023
Next filing
Sep 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Tax liability -$2.33K -541 -0.78% $4.30 69.2K Jun 1, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer.
F2 Includes 20,313 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.
F3 Includes 2,474 shares acquired under the Issuers Employee Stock Purchase Plan in May 2023.